For patients with colorectal cancer, the long-term use of statins is associated with better clinical outcomes

Ali A. Siddiqui, Hector Nazario, Amar Mahgoub, Mahir Patel, Daisha Cipher, Stuart J. Spechler

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Statins have been found to suppress tumor cell growth and to limit the ability of tumor cells to metastasize in studies involving cell lines and animals. To explore how the long-term use of statins influences the presentation and survival of patients with colorectal cancer (CRC), we conducted a retrospective case-control study of male patients with a new diagnosis of CRC who we categorized as: (1) Statin Users who used statins continuously ≥3 years prior to the diagnosis of CRC and (2) Statin Non-Users who did not use statins. Clinical factors were analyzed by simple Chi-square and multivariate regression analysis to identify independent predictors for advanced CRC. We identified 1,309 male patients with a new diagnosis of CRC (mean age 69 ± 1.1 (SE) years; 326 Statin Users, 983 Statin Non-Users). Compared to Statin Non-Users, Statin Users had a less advanced tumor stage (2.2 vs. 2.6; P < 0.01), a lower prevalence of metastases (OR = 0.7 [0.4-0.9, 95% CI]; P < 0.01), and a higher frequency of right-sided tumors (OR = 1.6 [1.3-2.1], 95%CI]; P < 0.01). Overall 5-year survival for Statin Users was 37% compared to 33% in Statin Non-Users (OR = 0.7 [0.6-0.9], 95%CI]; P = 0.03). In patients who present to the hospital with CRC, the long-term use of statins is associated with a less advanced tumor stage, a higher prevalence of right-sided tumors, a lower frequency of distant metastases, and a better survival rate.

Original languageEnglish (US)
Pages (from-to)1307-1311
Number of pages5
JournalDigestive Diseases and Sciences
Volume54
Issue number6
DOIs
StatePublished - Jun 2009

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Colorectal Neoplasms
Neoplasms
Neoplasm Metastasis
Survival
Case-Control Studies

Keywords

  • 3-Hydroxy-3-methyl glutaryl coenzyme A inhibitors
  • Colorectal cancer
  • Metastasis

ASJC Scopus subject areas

  • Gastroenterology
  • Physiology

Cite this

For patients with colorectal cancer, the long-term use of statins is associated with better clinical outcomes. / Siddiqui, Ali A.; Nazario, Hector; Mahgoub, Amar; Patel, Mahir; Cipher, Daisha; Spechler, Stuart J.

In: Digestive Diseases and Sciences, Vol. 54, No. 6, 06.2009, p. 1307-1311.

Research output: Contribution to journalArticle

Siddiqui, Ali A. ; Nazario, Hector ; Mahgoub, Amar ; Patel, Mahir ; Cipher, Daisha ; Spechler, Stuart J. / For patients with colorectal cancer, the long-term use of statins is associated with better clinical outcomes. In: Digestive Diseases and Sciences. 2009 ; Vol. 54, No. 6. pp. 1307-1311.
@article{e4f5050a12b546e5814b8756d0d6d91d,
title = "For patients with colorectal cancer, the long-term use of statins is associated with better clinical outcomes",
abstract = "Statins have been found to suppress tumor cell growth and to limit the ability of tumor cells to metastasize in studies involving cell lines and animals. To explore how the long-term use of statins influences the presentation and survival of patients with colorectal cancer (CRC), we conducted a retrospective case-control study of male patients with a new diagnosis of CRC who we categorized as: (1) Statin Users who used statins continuously ≥3 years prior to the diagnosis of CRC and (2) Statin Non-Users who did not use statins. Clinical factors were analyzed by simple Chi-square and multivariate regression analysis to identify independent predictors for advanced CRC. We identified 1,309 male patients with a new diagnosis of CRC (mean age 69 ± 1.1 (SE) years; 326 Statin Users, 983 Statin Non-Users). Compared to Statin Non-Users, Statin Users had a less advanced tumor stage (2.2 vs. 2.6; P < 0.01), a lower prevalence of metastases (OR = 0.7 [0.4-0.9, 95{\%} CI]; P < 0.01), and a higher frequency of right-sided tumors (OR = 1.6 [1.3-2.1], 95{\%}CI]; P < 0.01). Overall 5-year survival for Statin Users was 37{\%} compared to 33{\%} in Statin Non-Users (OR = 0.7 [0.6-0.9], 95{\%}CI]; P = 0.03). In patients who present to the hospital with CRC, the long-term use of statins is associated with a less advanced tumor stage, a higher prevalence of right-sided tumors, a lower frequency of distant metastases, and a better survival rate.",
keywords = "3-Hydroxy-3-methyl glutaryl coenzyme A inhibitors, Colorectal cancer, Metastasis",
author = "Siddiqui, {Ali A.} and Hector Nazario and Amar Mahgoub and Mahir Patel and Daisha Cipher and Spechler, {Stuart J.}",
year = "2009",
month = "6",
doi = "10.1007/s10620-009-0790-8",
language = "English (US)",
volume = "54",
pages = "1307--1311",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - For patients with colorectal cancer, the long-term use of statins is associated with better clinical outcomes

AU - Siddiqui, Ali A.

AU - Nazario, Hector

AU - Mahgoub, Amar

AU - Patel, Mahir

AU - Cipher, Daisha

AU - Spechler, Stuart J.

PY - 2009/6

Y1 - 2009/6

N2 - Statins have been found to suppress tumor cell growth and to limit the ability of tumor cells to metastasize in studies involving cell lines and animals. To explore how the long-term use of statins influences the presentation and survival of patients with colorectal cancer (CRC), we conducted a retrospective case-control study of male patients with a new diagnosis of CRC who we categorized as: (1) Statin Users who used statins continuously ≥3 years prior to the diagnosis of CRC and (2) Statin Non-Users who did not use statins. Clinical factors were analyzed by simple Chi-square and multivariate regression analysis to identify independent predictors for advanced CRC. We identified 1,309 male patients with a new diagnosis of CRC (mean age 69 ± 1.1 (SE) years; 326 Statin Users, 983 Statin Non-Users). Compared to Statin Non-Users, Statin Users had a less advanced tumor stage (2.2 vs. 2.6; P < 0.01), a lower prevalence of metastases (OR = 0.7 [0.4-0.9, 95% CI]; P < 0.01), and a higher frequency of right-sided tumors (OR = 1.6 [1.3-2.1], 95%CI]; P < 0.01). Overall 5-year survival for Statin Users was 37% compared to 33% in Statin Non-Users (OR = 0.7 [0.6-0.9], 95%CI]; P = 0.03). In patients who present to the hospital with CRC, the long-term use of statins is associated with a less advanced tumor stage, a higher prevalence of right-sided tumors, a lower frequency of distant metastases, and a better survival rate.

AB - Statins have been found to suppress tumor cell growth and to limit the ability of tumor cells to metastasize in studies involving cell lines and animals. To explore how the long-term use of statins influences the presentation and survival of patients with colorectal cancer (CRC), we conducted a retrospective case-control study of male patients with a new diagnosis of CRC who we categorized as: (1) Statin Users who used statins continuously ≥3 years prior to the diagnosis of CRC and (2) Statin Non-Users who did not use statins. Clinical factors were analyzed by simple Chi-square and multivariate regression analysis to identify independent predictors for advanced CRC. We identified 1,309 male patients with a new diagnosis of CRC (mean age 69 ± 1.1 (SE) years; 326 Statin Users, 983 Statin Non-Users). Compared to Statin Non-Users, Statin Users had a less advanced tumor stage (2.2 vs. 2.6; P < 0.01), a lower prevalence of metastases (OR = 0.7 [0.4-0.9, 95% CI]; P < 0.01), and a higher frequency of right-sided tumors (OR = 1.6 [1.3-2.1], 95%CI]; P < 0.01). Overall 5-year survival for Statin Users was 37% compared to 33% in Statin Non-Users (OR = 0.7 [0.6-0.9], 95%CI]; P = 0.03). In patients who present to the hospital with CRC, the long-term use of statins is associated with a less advanced tumor stage, a higher prevalence of right-sided tumors, a lower frequency of distant metastases, and a better survival rate.

KW - 3-Hydroxy-3-methyl glutaryl coenzyme A inhibitors

KW - Colorectal cancer

KW - Metastasis

UR - http://www.scopus.com/inward/record.url?scp=67349239967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349239967&partnerID=8YFLogxK

U2 - 10.1007/s10620-009-0790-8

DO - 10.1007/s10620-009-0790-8

M3 - Article

C2 - 19337834

AN - SCOPUS:67349239967

VL - 54

SP - 1307

EP - 1311

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 6

ER -